Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01612221 · ClinicalTrials.gov registry record · Phase 2
Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT01612221 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 100 participants.
The verdict
NCT01612221, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a phase II intervention to propose a new melanoma chemoprevention agent. The investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in humans can be inferred by protection of nevi from ultraviolet light (UV)-induced oxidative changes. The investigators will 1) evaluate whether administration of NAC around the time of UV exposure will reduce melanoma risk in high-risk patient populations with genetic susceptibility to UV-induced oxidative stress, and 2) examine key genetic variants that will identify which individuals are most likely to benefit from chemoprotection.
Interventions
- DRUG N-acetylcysteine
- OTHER Placebo arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-09 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01612221
The ClinicalTrials.gov registry entry for NCT01612221 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which N-acetylcysteine is the first listed.
NCT01612221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01612221 about?
NCT01612221 is a clinical study titled "Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo". This is a phase II intervention to propose a new melanoma chemoprevention agent. The investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in humans can be inferred by protection of nevi from ultraviolet light (UV)-in...
What is the current status of trial NCT01612221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2012-09. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01612221?
The interventions under investigation include: N-acetylcysteine (DRUG), Placebo arm (OTHER).
Who is sponsoring clinical trial NCT01612221?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.